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Introduction: Liver transplantation is the treatment of choice for decompensated liver
disease, and by extension for hepatic hydrothorax. Persistent pleural effusions make
it challenging for patients to maintain physiological fitness for transplantation. Indwelling
pleural catheters (IPCs) provide controlled pleural fluid removal, including peri-operatively.
The immune dysfunction of cirrhosis heightens susceptibility to bacterial infection and
concerns exist regarding the sepsis potential from a tunnelled drain.
Method: Six patients were identified who underwent IPC insertion for hepatic
hydrothorax before successful liver transplantation, between November 2016 and
November 2017.
Results: All patients had recurrent transudative right sided pleural effusions. Mean
age was 49 years (range 24–64) and mean United Kingdom Model for End-Stage
Liver Disease score was 58. Four patients required correction of coagulopathy before
insertion. There were no complications secondary to bleeding. Three patients were taught
self-drainage at home of up to 1 litre (L) daily. A protocol was developed to ensure weekly
review, pleural fluid culture and drainage of larger volumes in hospital. For every 2–3 L of
pleural fluid drained, 100 mls of 20% Human Albumin Solution (HAS) was administered.
On average an IPC was in situ for 58 days before surgery and drained 19 L of fluid in
hospital. There was a small increase in average BMI (0.2) and serum albumin (2.1 g/L)
at transplantation. There was one episode of stage one acute kidney injury secondary to
high volume drainage. No further ascitic or pleural procedures were needed while an IPC
was in situ. One thoracentesis was required after IPC removal. On average IPCs remained
in situ for 7 days post transplantation and drained a further 2 L of fluid. Pleural fluid
sampling was acquired on 92% of drainages in hospital. Of 44 fluid cultures, 2 cultured
bacteria. Two patients had their IPCs and all other lines removed post transplantation
due to suspected infection.
Conclusion: Our case series describes a novel protocol and successful use of IPCs
in the management of refractory hepatic hydrothorax as a bridge to liver transplantation.
The protocol includes albumin replacement during pleural drainage, regular clinical review
and culture of pleural fluid, with the option of self-drainage at home.
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INTRODUCTION
Hepatic hydrothorax is a pleural effusion in patients with
cirrhotic liver disease, without cardiopulmonary disease (1). It
is a complication in 5–10% of patients with cirrhosis (1–3), and
associated with significant morbidity (1, 4) andmortality (5). The
pathophysiology is believed to involve the direct movement of
ascitic fluid into the pleural cavity through diaphragmatic defects,
due to negative pressure within the pleural space (4, 6, 7).
Medical management typically involves a low salt diet and
diuretics, with therapeutic thoracentesis as required. Up to 26%
of hepatic hydrothoraxes will be refractory to treatment and
cause persistent symptoms such as cough and breathlessness
(4, 7). Management of refractory hepatic hydrothoraces has
historically proven to be difficult. Liver transplantation is
the treatment of choice for decompensated liver disease
(8), and by extension is the ideal management of hepatic
hydrothorax (9). This option is rarely immediately available
(10). Large, persistent pleural effusions make it challenging for
patients to maintain the physiological fitness required whilst
awaiting transplantation.
There has been increasing discussion regarding management
of hepatic hydrothorax in the bridging period to transplantation.
The aim is alleviation of dyspnoea with removal of pleural fluid,
however any intervention must be carefully weighed up against
the risks which could jeopardise a future lifesaving treatment.
Indwelling pleural catheters (IPCs), known to be effective in
management of malignant effusions, have been increasingly
used in management of benign pleural effusions (11).
IPCs are an attractive prospect in the management of
hepatic hydrothorax as they provide controlled pleural
fluid removal including in the peri-operative setting.
Given the immune dysfunction of cirrhosis, coupled with
increased translocation in portal hypertension, heightens
susceptibility to bacterial infection (12), concerns exist
regarding the sepsis potential from a tunnelled drain, that
could preclude transplantation.
This case series describes six patients who underwent IPC
insertion tomanage hepatic hydrothoraces, followed by definitive
liver transplantation.
METHOD
Six patients were identified who underwent IPC insertion for
hepatic hydrothorax between November 2016 and November
2017 at Cambridge University Hospital. All patients went on
to have successful liver transplantation. Information regarding
patient demographics, aetiology of liver disease, amount and
frequency of drainage, and serial microbiology and blood tests
results were obtained from the patient’s online notes, Epic R©
(Epic Systems Corporation). Verbal and written consent has been
obtained from all six patients.
Abbreviations: AKI, acute kidney injury; HAS, Human Albumin Solution; IPC,
indwelling pleural catheter; TIPSS, transjugular intrahepatic portosystemic shunt;
UKELD, United KingdomModel for End-Stage Liver Disease.
RESULTS
Demographics for our six patients are shown in Figure 1.
All six patients were inpatients under the care of the
hepatology team at the point of referral for IPC insertion
and suffered from recurrent right-sided transudative pleural
effusions. All had beenmedically managed with diuretics and had
at least one pleural procedure previously. None of the patients
had previously had transjugular intrahepatic portosystemic shunt
procedures. Their average United Kingdom Model for End-
Stage Liver Disease (UKELD) score was 58, suggesting a 1 year
mortality of between 9 and 50%.
All patients had a 16F tunnelled IPC inserted by the
interventional pleural team, under ultrasound guidance. Clotting
screen and platelet counts were checked in all patients pre-
procedure. At insertion the average international normalised
ratio (INR) was 1.4, and the average platelet count was 133
× 109/L.
Four patients had blood products given to correct
coagulopathies before the procedure was undertaken. All four
patients had fresh frozen plasma, two had platelet transfusions
and one was given intravenous vitamin K. During the procedure
all patients were given 15–20 mls of 2% local anaesthetic
with adrenaline (1:200,000) and there were no complications
secondary to bleeding.
Suitable patients (patients 4, 5 and 6 in Table 1) were trained
to use drainage kits at home to allow a maximum of 1 L daily
drainage, with weekly review by the pleural team to drain larger
volumes (to dryness) with albumin replacement. Patient 6 had
their follow-up reviews at their local hospital. Home drainage
was initiated immediately the day after insertion as these patients
had prior large volume aspirations without evidence of renal
compromise. Those patients who drained their IPC at home
reported daily drainage of close to 1 L to their clinicians. The
volume of fluid drained at home is included in the data inTable 1,
though the total amount drained is based on an estimate as there
were no complete formal records of home drainage.
A local protocol, based on our institution’s peritoneal drainage
protocol, was developed in conjunction with our Hepatology
department to ensure regular in person review, regular culturing
FIGURE 1 | Demographics. *A United kingdom Model for End-Stage Liver
Disease (UKELD) score of 49 indicates a 9% 1-year risk of mortality, and a
score of 60 indicates a 50% chance of 1-year survival (13).
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TABLE 1 | Results.
Patient 1 2 3 4 5 6 Mean
Before insertion of drain
Ascitic drains in 12 month prior 3 0 >3 1 2 0
Previous pleural procedures 3 1 2 1 2 4 2.2
Between insertion and transplant
Insertion to transplant (days) 78 16 3 82 135 31 57.5
Total drain time in situ (days) 85 21 5 92 140 46 64.8
BMI change 0.9 (+) 0 0 1.1 (+) 0.4 (+) 1.0 (–) 0.2 (+)
Serum Albumin change 7 (–) 9 (+) 8 (+) 2 (–) 1 (+) 4 (+) 2.1 (+)
Pre-transplant drain output in hospital (L) 35 14.6 5.3 26 31.2 1.5 18.9
Total estimated pre-transplant drain output total including home drainage (L) 35 14.6 5.3 97 146.2 31 54.8
Total times drained in hospital 9 6 1 11 20 1 8.0
Total times drained (estimated) including home drainage 9 6 1 82 135 31 51.8
Average output in hospital per drainage (L) 3.9 2.4 5.3 2.4 1.6 1.5 2.9
Average output per drainage (based on total estimated) 3.9 2.4 5.3 1.2 1.1 1 2.5
20% HAS requirements (L) 1.2 1.4 0.3 1.2 2.6 0.4 1.2
Fluid cultures sampled 9 2 1 10 20 2 7.3
Post transplantation
Days drain in situ post-transplant 6 5 2 10 5 15 7.2
Post transplantation drain output (L) 1.7 2 0.4 1 3.9 3.4 2.1
of pleural fluid and supervised drainage of larger volumes of fluid
in hospital (for both inpatients and outpatients). For every 2–3
litres of pleural fluid drained, 100 mls of 20% Human Albumin
Solution (HAS) was administered, with a view to reduce the risk
of circulatory dysfunction and renal impairment. The volume of
albumin administered was calculated based on the total drainage
for the week, including drainage at home and on the day of review
in hospital.
This protocol is illustrated in Figure 2.
On average an IPC was in situ for 58 days before surgery, with
an average drainage of 19 litres of fluid in hospital in this time
period. Pleural fluid culture sampling was acquired on 92% of
drainages in hospital. Of the 44 fluid pleural fluid cultures sent on
our series, two cultured bacteria – Acinetobacter Iwoffi (a known
skin coloniser) and Streptococcus parasanguinis.
The IPCs remained in situ for an average of 7 days post liver
transplantation and on average drained 2 litres of pleural fluid
after surgery. One patient required a single further thoracentesis
post IPC removal. No patients required further ascitic or pleural
drainage while the IPC was in situ.
Our patients on average had a small increase in albumin and
BMI between insertion of the IPC and liver transplantation. A
single patient had a single episode of stage I AKI associated with
high volume pleural drainage, as described above, despite human
albumin replacement. There was no significant derangement
in sodium or creatinine associated with pleural drainage seen
otherwise. All patients remain under ongoing follow up by the
Hepatology team at our institution.
Table 1 summarises the individual data collected from our six
patients.
One patient was noted to have a pneumothorax on their post
IPC insertion chest x ray – to manage this the IPC was connected
to an underwater seal and not clamped. As a result, pleural fluid
FIGURE 2 | Protocol.
drainage was not controlled. Though 20% HAS was given, this
resulted in acute kidney injury (AKI) stage 1, which resolved
within a few days. The pneumothorax resolved within 24 h, and
was likely related to high volume drainage.
There were no complications secondary to infection in our
series prior to transplantation. One pleural drain was removed
(in addition to all other lines and drains) in a patient after
transplantation due to pyrexia of unknown source. Streptococcus
parasanguinis was cultured post transplantation from pleural
fluid on one occasion. This patient subsequently required one
further thoracentesis after IPC removal. Another patient had
their pleural drain removed on day 15 after transplant as a
precaution due to a suspected infection of unknown source.
No organisms were cultured in pleural fluid, sampled at the time
of removal of the IPC.
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PATIENT PERSPECTIVE
All our patients reported breathlessness as a symptom (to varying
degrees) and reported an improvement in breathlessness with
drainage of pleural fluid. One of our patients had a limited
memory of that time period, and had their IPC in situ for a short
period of time.
The remaining patients stated a preference for IPC
management of their pleural effusions, compared to repeated
thoracentesis. Their comments included that repeat therapeutic
aspirations tended to be time consuming and uncomfortable,
and performed on an emergency basis.
Our patients spoke favourably of having weekly clinical
review, and did not mind the distance required to travel to
hospital. One patient described feeling more secure knowing that
they would have regular scheduled review, and all patients spoke
positively of the relationship that was built due to the continuity
of care.
Three of our patients performed regular drainages away from
the hospital – one at their local surgery, and two at home, with
their spouses performing drainage. All three spoke favourably
of home drainage, citing increased autonomy and having more
control of their own symptoms. They reported no technical issues
with draining their IPCs, and all had a point of contact for
any concerns.
One patient reported mild discomfort at the site following
insertion. Another, who had been taught to access the IPCs while
they were in hospital, described that they had less confidence in
ward nurses unfamiliar with IPCs.
Our patients expressed positive sentiment towards IPC
management of their effusions, with all patients stating they
would opt for a tunnelled drain should they have to go through
a similar presentation again. In particular, the autonomy and
comfort of home drainage (or the potential of it) was mentioned
as a positive, as was the comparison with experiences of recurrent
aspirations prior to drain insertion.
DISCUSSION
We report a case series of six patients who successfully underwent
IPC insertion for refractory hepatic hydrothorax as a bridge
to liver transplant. We believe this is the largest case series in
the UK. This remains an ongoing approach, with three further
patients managed since our case series, all undergoing IPC
insertion as bridging to successful liver transplantation.
Management of hepatic hydrothorax is centred around
alleviating dyspnoea by control or removal of pleural fluid which
can rapidly reaccumulate. Bhatnagar et al. analysed the data from
57 patients who underwent IPC insertion for benign pleural
effusions, including 19 patients with hepatic hydrothorax who
were not listed for transplant and found that patients with hepatic
hydrothorax had undergone more pleural procedures before IPC
insertion (median 4.5) with higher volumes of average weekly
drainage (5.14 L per week) (11). Our patients drained an even
higher estimated volume of 6.79 L per week.
Chest tube insertion in this context has been shown to carry
increased morbidity and mortality with complications including
renal dysfunction (14, 15). High volume drainage of fluid and
re-accumulation of pleural fluid on clamping intercostal drains
is characteristic. As a result, repeat thoracentesis has been the
routine procedure for removal of pleural fluid from the pleural
cavity and has been shown to have reducedmortality and hospital
stay compared to chest drain insertion (16). However, a single
centre retrospective review of patients undergoing thoracentesis
showed the cumulative risk of complications increased with
sequential thoracenteses (17), with increased risk of haemothorax
with thrombocytopenia and higher MELD scores (Model for
End-Stage Liver Disease which stratifies severity of liver disease).
Repeated thoracentesis has also been shown to be associated with
increased hospital cost and longer length of stay (18).
TIPSS (transjugular intrahepatic portosystemic shunt)
procedures have been shown to be effective in the treatment
of refractory hepatic hydrothorax. In a study of 24 consecutive
patients with cirrhosis there was improvement in symptoms
in 79% of patients. However, complete relief of symptoms was
found to occur in only 58% of patients, with a further 21% of
patients requiring further thoracentesis post procedure (19). A
systematic review and meta-analysis found similar figures, with
a complete response in 55% of patients, partial response in 18%
of patients and an absent response in 21% of patients (20).
As IPCs are being more commonly used in the management
of benign effusions, there is increasing work looking at a possible
role in treating hepatic hydrothoraces, including bridging to
transplantation and as palliation. A single-centre prospective
feasibility study of 25 prospective liver transplant candidates
who underwent IPC insertion for hepatic hydrothorax included
five patients who went on to have liver transplantation (21).
A retrospective review of sixty-two patients over a 10 year
period who underwent IPC insertion for hepatic hydrothorax at
a single referral centre, included ten patients who were bridged
successfully to liver transplantation (22). The only multicentre
retrospective review of use of IPC in hepatic hydrothorax
included four patients who underwent liver transplantation (23).
In theory the use of an IPC to allow bridging to transplant is
an attractive option. It allows controlled pleural fluid drainage in
an inpatient or outpatient setting, and also allows the possibility
of patients being able to access the drain at home for regular
drainage. Given the large volumes of fluid that were drained
in our series, this reduces emergency admissions and length of
hospital stay due to breathlessness and importantly gives patients
increased autonomy. In our case series no further pleural nor
ascitic procedures were required while the IPCs were in situ.
IPCs also provide the possibility for controlled drainage
peri-operatively, without need for further procedures. This was
evident in our case series, with two patients draining in excess
of 3 litres of fluid post-operatively before IPC removal. Post-
operative chest drainage was explored in a retrospective study
of 597 patients who underwent liver transplantation in which as
many as 361 (60%) patients required a chest drain within the first
10 days of surgery (24).
Spontaneous pleurodesis did not occur before liver
transplantation in any of our patients. Chen et al. found a
spontaneous pleurodesis rate of 33% in their prospective study of
IPC in hepatic hydrothorax with an average time to pleurodesis
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of 132 days (21), a longer period on average than patients in our
series had their IPC in situ before transplantation. Bhatnagar
et al. found a median pleurodesis time of 222 days and lower
pleurodesis rate (11%) in hepatic hydrothorax compared to
effusions due to other pathologies and suggested IPC use as
a long-term symptomatic palliative measure or as a bridge to
transplantation (11).
Two of our patients had their IPCs removed post-operatively,
in addition to all other lines, due to suspected infection. This
highlights the concerns regarding pleural infection associated
with long term indwelling pleural catheters. In the multicentre
retrospective study by Shojaee et al. of 79 patients who had IPC
inserted due to hepatic hydrothorax, they found a 10% overall
infection rate and 2.5% mortality rate because of IPC-related
empyema and sepsis. Of particular concern, IPC prevented liver
transplant in one patient because of IPC-related sepsis and death
(23). In the retrospective study of 62 patients by Kniese et al.
two patients who were listed for transplant died secondary to
IPC-related empyema. This study described an 18% incidence
of pleural infection (22). The single centre prospective feasibility
study by Chen et al. found pleural infection rates of 16%, however
with no associated mortality (21).
In a recent editorial, Walker and Maldonado describe
the difficulties of characterising pleural infection in hepatic
hydrothorax, in particular due to the rate of spontaneous
bacterial empyema (25) (13%) and colonisation of the IPC that
can be difficult to distinguish from genuine pleural infection.
Despite this, the rates of infection and mortality described in
a cohort of patients awaiting a potentially lifesaving procedure
necessitate high levels of vigilance. As a result, they advise that
IPCs “should be considered with great caution in patients eligible
for liver transplantation” (26).
We specifically developed a local protocol (see Figure 2) as
a safety mechanism to be able to respond to potential infection
promptly. It ensured weekly clinical review by the pleural team,
culture of pleural fluid in the majority of drainages in hospital
and regular monitoring of inflammatory markers. This was
particularly important in our series, which involved patients
accessing the drain at home (after thorough training). There
were no complications secondary to infection in our series prior
to transplantation.
The retrospective study by Kniese et al. showed a small
downward trend in albumin and BMI in their cohort of patients
(22). It is unclear if replacement of pleural fluid with HAS,
might reduce nutritional or electrolyte derangement (26). HAS
is used routinely in large volume paracentesis and recommended
by the American Association for the Study of Liver Diseases
(27) and the European Association for Study of the Liver (28).
A systematic review and meta-analysis suggested that “use of
albumin in paracentesis was associated with significantly reduced
risk of paracentesis-induced circulatory dysfunction (OR 0.26
95%, CI 0.08–0.93) and there was a non-significant difference
in death, encephalopathy, hyponatraemia, readmission and renal
impairment” (29). In our series patients were given 100 mls of
20% HAS for every 2–3 litres of pleural fluid drained, as per the
agreed protocol with our Hepatology department. Apart from
a single episode of stage 1 acute kidney injury, there was no
significant derangement in sodium or creatinine associated with
pleural drainage seen.
There are several limitations to our study. A dyspnoea
assessment was not used to assess for any improvements in
quality of life, though an improvement in breathlessness was
described by all patients. Selection bias is likely as this is a small
case series of patients who were selected as they successfully
underwent liver transplantation. Additionally, for three of our
patients the total volume of fluid drained during our study was
estimated based on their verbal report, as there was no complete
formal record of the daily volume drained by patients at home.
CONCLUSION
Our case series offers a description of successful use of IPCs as
management of refractory hepatic hydrothorax as a bridge to
liver transplantation, using a novel protocol in which albumin
replacement was given during pleural drainage, with weekly
clinical review, regular culture of pleural fluid and monitoring
of electrolytes, renal function and inflammatory markers.
Larger retrospective studies have raised concerns regarding
the potential for infection precluding liver transplantation, but
have suggested a role for IPCs in palliation. A randomised
controlled trial assessing the use of IPC’s, as well as the
role of albumin replacement, in hepatic hydrothorax as a
bridge to transplantation, using a standardised management and
monitoring protocol, is required.
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